ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 23 of 221 for:    heart disease AND stroke AND California

Markers of Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02734758
Recruitment Status : Recruiting
First Posted : April 12, 2016
Last Update Posted : July 13, 2017
Sponsor:
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
This study will evaluate whether a gene marker can improve the identification of atrial fibrillation in patients with ischemic stroke, and evaluate whether the decision to anticoagulate could be improved by a marker of atrial fibrillation.

Condition or disease
Stroke Atrial Fibrillation

Detailed Description:

Atrial fibrillation (AF) is a major cause of ischemic stroke that is critical to identify because anticoagulation provides a 66% risk reduction in recurrent stroke. However, opportunities to prevent stroke due to AF are frequently missed because AF is paroxysmal and therefore not detected at the time of stroke. In addition, even when AF is identified anticoagulation may not be initiated due to perceived contraindications.

This study will (1) evaluate whether a gene marker can improve the identification of AF in patients with ischemic stroke, and (2) evaluate decisions by health care provider and patients to anticoagulate AF, and whether this decision could be improved by a marker of AF at time of stroke. An AF Gene Score will be developed comprised of genes associated with inflammatory and thrombotic pathways related to risk of AF thromboembolism in stroke patients with AF. The AF Gene Score measured at time of stroke can stroke will permits rapid identification of stroke due to AF which may increase initiation of anticoagulation therapy. This is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty regarding the association of delayed AF with initial stroke and delays anticoagulation.


Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Atrial Fibrillation in Ischemic Stroke: Strengthening Identification and Decisions to Anticoagulate
Actual Study Start Date : August 2011
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
Atrial fibrillation stroke
Non-atrial fibrillation Stroke



Primary Outcome Measures :
  1. Gene expression [ Time Frame: Post stroke through study completion, an average of 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with ischemic stroke
Criteria

Inclusion Criteria:

  • Ischemic stroke within 72 hours of onset
  • Complete evaluation to determine cause of stroke
  • Informed Consent

Exclusion Criteria:

  • Active Infection
  • Lymphoma / Leukemia / Blood dyscrasia
  • Hemorrhagic stroke
  • Immunosuppressive therapy
  • Illicit drug use
  • Blood transfusion +/- 1 month
  • Major surgery/trauma in last 6mts

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02734758


Contacts
Contact: Glen Jickling gcjickling@ucdavis.edu

Locations
United States, California
University of California Davis Recruiting
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis

Responsible Party: University of California, Davis
ClinicalTrials.gov Identifier: NCT02734758     History of Changes
Other Study ID Numbers: 248994
First Posted: April 12, 2016    Key Record Dates
Last Update Posted: July 13, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Heart Diseases
Atrial Fibrillation
Pathologic Processes